EUCTR2018-000383-28-DE进行中（未招募）1 期
Perioperative immunotherapy vs. chemo-immunotherapy stratified by early response evaluation in patients with advanced gastric cancer (GC) and adenocarcinoma of the esophago-gastric junction (AEG)(IMAGINE) - IMAGINE
niversity Hospital Essen0 个研究点目标入组 44 人开始时间: 2018年7月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Histologically confirmed, resectable GC or AEG (AEG I-III) (uT2, uT3, uT4, any N category, M0), or any T N+ M0 patient, with the following specifications:
- •- Exclusion of distant metastases by CT or MRI of abdomen, pelvis, and thorax, bone scan or MRI (if bone metastases are suspected due to clinical signs). Exclusion of the infiltration of
- •any adjacent organs or structures by CT or MRI
- •- Measurable target tumors using standard imaging techniques or clinical evaluation and significant FDG-uptake in PET
- •- Female and male patients = 18. Patients in reproductive age must be willing to use adequate contraception during the study and for 6 months after the end of treatment. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.
- •- Eastern Cooperation Oncology Group (ECOG) = 1
- •- Adequate hematological, hepatic and renal function parameters:
- •o Leukocytes = 2000/mm³, platelets = 100,000/mm³, absolute neutrophil count (ANC) =1500/µL, hemoglobin =9 g/dL (5.58 mmol/L),
- •o Adequate coagulation function as defined by International Normalized Ratio (INR) = 1.5, and a partial thromboplastin time (PTT) = 5 seconds above the upper limit of normal (ULN) (unless receiving anticoagulation therapy). Patients receiving warfarin/ phenprocoumon must be switched to low molecular weight heparin and have achieved stable coagulation profile prior to randomization.
- •o Serum creatinine = 1.5 x ULN of normal or calculated creatine clearance of < 50 mL/min (using Cockroft-Gault formula)
- •o Bilirubin = 1.5 x ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 x ULN, alkaline phosphatase = 6 x ULN, Serum albumin =2.8 g/dL
- •- Left ventricular ejection fraction (LVEF) assessment with documented LVEF =50% by either trans-thoracic echocardiography (TTE) or multigated acquisition (MUGA) (TTE preferred test) within 6 months from first study drug administration
- •- Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures
- •- Optional, if further IO combination will be added per amendment: positive Biomarker expression (i.e. LAG-3) if data from previous clinical trials support the use of IO combination in selected patients
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 22
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 22
排除标准
- •1. Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, anti-phospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis with the following exceptions:
- •-- Patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study.
- •-- Patients with controlled type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
- •-- Skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic immunosuppressive treatment, in particular corticosteroids are permitted to enroll
- •2. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration
- •3. Uncontrolled or significant cardiovascular disease including, but not limited to, any of the following:
- •o Myocardial infarction (MI) or stroke/transient ischemic attack (TIA) within the 6 months prior to consent
- •o Uncontrolled angina within the 3 months prior to consent
- •o Any history of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
- •o QTc prolongation > 480 msec
- •o History of other clinically significant cardiovascular disease (i.e., cardiomyopathy, congestive heart failure with New York Heart Association [NYHA] functional classification III-IV, pericarditis, significant pericardial effusion, significant coronary stent occlusion, deep venous thrombosis, etc )
- •o Cardiovascular disease-related requirement for daily supplemental oxygen
- •o History of two or more MIs OR two or more coronary revascularization procedures
- •o Subjects with history of myocarditis, regardless of etiology
- •o Troponin T (TnT) or I (TnI) > 2 × institutional ULN. Subjects with TnT or TnI levels between > 1 to 2 × ULN will be permitted if repeat levels within 24 hours are 1 x ULN.
- •4. Active malignancy or a prior malignancy within the past 3 years
- •o Patients with completely resected basal cell carcinoma, cutaneous squamous cell carcinoma, cervical carcinoma in-situ, breast carcinoma in-situ, and patients with isolated elevation in prostate-specific antigen in the absence of radiographic evidence of metastatic prostate cancer are eligible for the study.
- •5. Positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). NOTE: Testing for HIV must be performed at sites where mandated locally.
- •6. Any positive test result for hepatitis B virus or hepatitis C virus indicating presence of virus, e.g., hepatitis B surface antigen (HBsAg, Australia antigen) positive, or hepatitis C antibody (anti-HCV) positive (except if HCV RNA negative).
- •7. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
- •8. Peripheral polyneuropathy = NCI Grade II
- •9. Confirmed history of encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent
- •10. History of gastric perforation or fistulae in past 6 months
- •11. Serious or non-healing
研究者
相似试验
进行中（未招募）
2 期
Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEGAdenocarcinoma of the Esophagogastric JunctionGastric CancerNCT04062656University Hospital, Essen21
进行中（未招募）
1 期
Peri-operative Immuno-Chemotherapy in Operable oesophageal aNd gastrIc CancerEUCTR2016-003306-13-GBThe Royal Marsden NHS Foundation Trust53
尚未招募
2 期
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung CancerStage II-IIIB(N2) Non-small Cell Lung CancerNCT06109402Shanghai Pulmonary Hospital, Shanghai, China160
进行中（未招募）
1 期
Peri-operative association of immunotherapy in oeso-gastric adenocarcinomaEUCTR2018-004712-22-FRGERCOR32
已完成
2 期
Postoperative adjuvant immunochemotherapy of tumor specific peptide vaccine plus CDDP+5FU chemotherapy for esophageal cancer patients with pathological lymph node metastasis who underwent no preoperative treatment- Multicenter Phase II trialesophageal cancerJPRN-UMIN000003556Kinki University Faculty of Medicine60